TP53 and B-cell chronic lymphocytic leukemia: Choosing the most appropriate therapy in patients with relapsed/refractory CLL requires not only, as with first-line CLL therapy, an assessment of the patient’s comorbidities, frailty and TP53 mutational pattern, but also further consideration of previously received therapies and outcomes.